A5062759239- Diabetes Treatment and Management
- COVID-19 Clinical Research Studies
- PARP inhibition in cancer therapy
- Pancreatitis Pathology and Treatment
- Neuroendocrine Tumor Research Advances
- Metabolism, Diabetes, and Cancer
- SARS-CoV-2 and COVID-19 Research
Novo Nordisk (Denmark)
2022-2024
People with type 2 diabetes are at heightened risk for severe outcomes related to COVID-19 infection, including hospitalization, intensive care unit admission, and mortality. This study was designed examine the impact of premorbid use glucagon-like peptide-1 receptor agonist (GLP-1RA) monotherapy, sodium-glucose cotransporter-2 inhibitor (SGLT-2i) concomitant GLP1-RA/SGLT-2i therapy on severity in individuals acute respiratory syndrome coronavirus (SARS-CoV-2) infection. Utilizing...
Background While vaccination is the most important way to combat SARS-CoV-2 pandemic, there may still be a need for early outpatient treatment that safe, inexpensive, and currently widely available in parts of world do not have access vaccine. There are in-silico, in-vitro, in-tissue data suggesting metformin inhibits viral life cycle, as well observational use before infection with SARS-CoV2 associated less severe COVID-19. Previous analyses from single-center cohorts been limited by size....